More than 18 million people worldwide suffer from rheumatoid arthritis, including nearly 1.5 million Americans. Rheumatoid arthritis is an autoimmune, inflammatory form of arthritis, meaning a ...

Dr. Deane has received grant funding from the Arthritis Foundation, the National Institutes of Health, Boehringer Ingelheim, Gilead and ThermoFisher, and has had consulting/advisory board ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation throughout the body and most often affects the joints, leading to pain, stiffness, swelling, and reduced mobility.

The Detroit Lions unexpectedly had a question mark at the wide receiver position going into the Week 17 game against the Minnesota Vikings after Amon-Ra St. Brown was on the injury report this week.

Please provide your email address to receive an email when new articles are posted on . Rosnilimab depletes pathogenic T cells in patients with RA. Patient-reported data showed clinically important ...

It is now officially crunch time for several NFL teams, as the race for the playoffs has begun to intensify. This is actually the first time in NFL history where there are five divisions that include ...

Rheumatoid arthritis begins years before pain ever appears, and scientists have now mapped the hidden immune battle that unfolds long before symptoms. By studying people with RA-linked antibodies over ...

Brookfield Real Assets Income Fund is downgraded to a sell due to persistent NAV decline and unsustainable dividend coverage. RA's high 10.7% yield is attractive, but earnings consistently fall short ...

Amon-Ra St. Brown knew his audience. The Lions’ star receiver broke out the “Trump Dance” during Sunday’s game against the Commanders with President Donald Trump in attendance at Northwest Stadium.

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

Rosnilimab, a selective depleter of pathogenic T cells, is a potential game changer for the treatment of moderate-to-severe rheumatoid arthritis (RA). In a new Phase 2b clinical trial, rosnilimab ...

Polypharmacy in RA patients is linked to increased drug interaction risks, especially with immunosuppressants, necessitating careful management and monitoring. Older age and multiple comorbidities are ...